Formulation Development
Liminatus Pharma R&D Consortium Companion Diagnostic YN 1203 Demonstrates ~70% Sensitivity & Specificity in Clinical Testing
Liminatus Pharma recently announced its companion diagnostic to support checkpoint inhibitor therapies, YN1203 CDx liquid biopsy test (YN1203 ELISA Kit), has demonstrated….
Cyclerion Therapeutics Announces Global Licensing Agreement With Akebia Therapeutics
Cyclerion Therapeutics, Inc. recently announced it has entered into an exclusive, global license agreement with Akebia Therapeutics, Inc., a leading biopharmaceutical company focused on kidney disease, for the….
Bayer to Advance Two First-of-its-Kind Cell & Gene Therapies for Parkinson’s Disease
Bayer AG recently announced that BlueRock Therapeutics (BlueRock) successfully administered the first dose of its pluripotent stem cell-derived dopaminergic neurons, named DA01, to a….
Akoya & AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology
Akoya Biosciences, Inc. recently announced a collaboration with AstraZeneca to advance new multiplex immunofluorescence (mIF) workflows and spatial biomarker signatures….
Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-Targeting TriTAC HPN424
Harpoon Therapeutics, Inc. recently presented interim data from the ongoing dose-escalation portion of a Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostate…
iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of its Adenosine A2A Receptor Antagonist
iTeos Therapeutics, Inc. recently announced new clinical data from its ongoing Phase 1/2a clinical trial of inupadenant (EOS-850), a next-generation adenosine receptor (A2AR) antagonist, at…
IN8bio Completes Treatment of First Cohort in Phase 1 Clinical Trial With Gamma Delta T-Cell Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme
IN8bio, Inc. recently announced an update from the ongoing Phase 1 clinical trial of INB-200, its DeltEx drug resistant immunotherapy (DRI), MGMT-gene modified gamma delta…
Cullinan Oncology Announces Phase 1/2a Interim Data for Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
Cullinan Oncology, Inc. recently announced additional details pertaining to Cullinan Pearl’s ongoing Phase 1/2a trial of CLN-081 in Non-Small Cell Lung Cancer (NSCLC) patients whose…
Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
Addex Therapeutics recently announced the first patients have been enrolled into a Phase 2 clinical study evaluating JNJ-40411813 (ADX71149) in patients with epilepsy. JNJ-40411813 (ADX71149)…
Mirati Therapeutics & Zai Lab Enter Development & Commercialization Collaboration
Mirati Therapeutics, Inc. and Zai Lab Limited recently announced the companies have entered into a collaboration and license agreement for adagrasib, a small-molecule….
Immutep Enters Into New Collaboration With Merck KGaA
Immutep Limited recently announced a new collaboration and supply agreement with Merck KGaA , Darmstadt, Germany, for a Phase 1/2a clinical trial in patients with….
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline Into Cancer & Fibrotic Diseases
Corbus Pharmaceuticals Holdings, Inc. recently announced licensing deals for two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of….
Aptamer Group Collaborates With World-Leading Pharmaceutical Company to Evaluate Optimer Technology
Aptamer Group recently announced that it has signed an agreement with the multinational pharmaceutical and biopharmaceutical company Takeda Pharmaceutical Company Limited…..
Hovione & iBET Announce Strategic Collaboration
Hovione was a founding member of iBET in 1989 and has just re-joined the membership of the Instituto de Biologia Experimental e Tecnológica. In order…
PDS Biotechnology Establishes Partnership With Head & Neck Cancer Alliance
PDS Biotechnology Corporation and the Head and Neck Cancer Alliance (HNCA) recently announced a partnership that seeks to raise awareness of new and developing treatment…
Santhera & ReveraGen Announce Positive & Statistically Highly Significant Topline Results
Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. recently announced positive key results from the VISION-DMD study, demonstrating robust efficacy across multiple efficacy endpoints and favorable safety…
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. recently announced the US FDA has extended the review period for the New Drug Application (NDA) for VP-102 for the treatment of…
uniQure Announces Positive Recommendation to Advance Phase 1/2 Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. recently announced the independent Data Safety Monitoring Board (DSMB) overseeing the Phase 1/2 clinical trial of AMT-130 for the treatment of Huntington’s disease…
Ocugen On Track to Submit EUA Application to US FDA for its COVID-19 Vaccine Candidate
Ocugen, Inc. recently confirmed its plan to submit its Emergency Use Authorization (EUA) application for COVAXIN to the US FDA in June. “Since we have…
WEARABLE PLATFORM - Next-Generation Wearable Drug Delivery: Prefilled Devices Provide a Truly Patient-Centric Solution
Mindy Katz says with increasingly positive expectations for the wearable device market to provide an intuitive and user-friendly drug delivery experience, her company continues to optimize its wearable platform solution, investigating new technologies and processes to improve the offerings for patients and providers.
